Showing 5331-5340 of 20465 results for "".
- Glucose Metabolism as a Key Driver in Metabolic-Related Liver Diseaseshttps://reachmd.com/news/glucose-metabolism-as-a-key-driver-in-metabolic-related-liver-diseases/2484228/An NHANES analysis finds glycemic markers—fasting glucose, HbA1c and insulin-resistance indices—track more closely with hepatic steatosis and liver s
- Early-Life Stress: A Risk Factor for Developing Psoriasishttps://reachmd.com/news/early-life-stress-a-risk-factor-for-developing-psoriasis/2484234/A Swedish birth‑cohort analysis found that changes in family structure during infancy were associated with an almost threefold increase in later‑life psoriasis. Th
- TrUE-AD4: Opzelura Shows Rapid, Significant Efficacy in Moderate ADhttps://reachmd.com/news/true-ad4-opzelura-shows-rapid-significant-efficacy-in-moderate-ad/2484225/New data from Incyte’s phase 3b TRuE-AD4 trial show that Opzelura® (ruxolitinib cream 1.5%) improved clinical symptoms of moderate atopic dermatitis (AD) in adults with limited response or intolerance to standard thearpy. The
- Neutrogena Recalls Makeup Wipes Due to Bacterial Contaminationhttps://reachmd.com/news/neutrogena-recalls-makeup-wipes-due-to-bacterial-contamination/2484214/The Food and Drug Administration (FDA) issued a Class II risk level for a line of Neutrogena's makeup-removing facial wipes due to potential bacterial infection, according to a statement from the agency. In a brief message, the FDA reported that an internal investigation by the manufacture
- Evaluating the Potential New Standard for HER2-Expressing Urothelial Carcinomahttps://reachmd.com/news/evaluating-the-potential-new-standard-for-her2-expressing-urothelial-carcinoma/2484109/In a pivotal Phase III trial presented at the 2025 ESMO
- Advancements and Challenges in Ultrasound AI for Ovarian Tumor Detectionhttps://reachmd.com/news/advancements-and-challenges-in-ultrasound-ai-for-ovarian-tumor-detection/2484111/A multicenter retrospective study shows that combining a ResNet-50 visual model with LLM-generated descriptions improves static-ultrasound classification of ovarian tumors, boosting class-specific accuracy and narrowing sonographer variability, according to
- H9N2: Emerging Threat of a Potential Human Pandemichttps://reachmd.com/news/h9n2-emerging-threat-of-a-potential-human-pandemic/2484105/According to a Nature report, recent H9N2 avian influenza variants show genetic changes that increase binding to human-like receptors, raising
- CollPlant Launches US Logistics Hub to Support North American Growthhttps://reachmd.com/news/collplant-launches-us-logistics-hub-to-support-north-american-growth/2484120/CollPlant Biotechnologies has expanded its North American operations through a new partnership with a US-based logistics hub, the company announced. The center, expected to become operational this quarter, will support the growing distribution needs for CollPlant’s recombinant human collagen (rhC
- Bimekizumab Maintains Flare Control in HS Through 2 Yearshttps://reachmd.com/news/bimekizumab-maintains-flare-control-in-hs-through-2-years/2484119/Bimekizumab provides sustained control of disease flares in patients with moderate-to-severe hidradenitis suppurativa (HS), with more than 83% of patients remaining flare-free over 96 weeks, according to interim results from the BE HEARD EXT study presented by Dr. H
- Combination of Clascoterone 1% and Adapalene 0.3% Shows Promise for Acnehttps://reachmd.com/news/combination-of-clascoterone-1-and-adapalene-03-shows-promise-for-acne/2484118/Combination therapy with clascoterone cream 1% and adapalene gel 0.3% significantly improves acne severity and quality of life, while maintaining excellent tolerability in patients with moderate-to-severe acne vulgaris, according to a 16-week pilot study presented